Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00358371 | Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg) | PHASE1 | COMPLETED | 24 | — | — | Jan 6, 2005 | Feb 8, 2005 | Sep 29, 2017 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| Subjects receiving flucloxacillin 250 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| Subjects receiving flucloxacillin 500 mg | EXPERIMENTAL | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
| Name | Type | Description |
|---|---|---|
| flucloxacillin 250 mg | DRUG | Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose |
| flucloxacillin 500 mg | DRUG | Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose |
Inclusion Criteria: * Healthy volunteers, * Caucasians, * Body Mass Index (BMI) between 19 and 27 kg/m 2; * physically and mentally healthy as judged by means of a medical and standard lab examination; * non-smokers, * ex-smokers or moderate smoker. Exclusion criteria: * medical history, * vital ...